Evogene Ltd (EVGN)

[Jaydixson1]

Ark has been buying evgn

[midastouch017]

Lavie Bio Provides Product Pipeline Update for 2020

Tue, December 29, 2020, 2:00 PM GMT+2

LAV211 bio-stimulant advancing towards anticipated 2022 commercial launch in spring wheat; Product advancement achieved in multiple programs

REHOVOT, Israel, Dec. 29, 2020 /PRNewswire/ -- Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), has announced an update on certain advancements achieved in its pipeline in 2020, including phase advancement of bio-stimulant LAV211, towards an anticipated commercial launch in 2022.

"Our commitment and main focus at Lavie Bio is to develop novel microbiome based ag-biological products, bio-pesticides & bio-stimulants that address the dire need for new tools to increase agriculture productivity while improving sustainability and food quality. 2020 was a remarkable year in our journey to achieve these targets," stated Mr. Ido Dor, CEO of Lavie Bio.

Bio-stimulants pipeline:

LAV211 Bio-stimulant Targeting Spring Wheat – Initially targeting approximately 25 million acres of spring wheat in North America,[1] LAV211 is Lavie Bio's leading product candidate in this program. According to Lavie Bio's estimates, and assuming current agricultural commodity prices, a viable and effective bio-stimulant could generally be expected to provide farmers with additional value that translates to at least $20, on average, of income per farmed acre.

LAV211 is advancing into the pre-commercial phase,[2] following field trials in target locations, meeting development criteria and outperforming trial controls, which included competitor benchmarks. Additionally, LAV211 received product registration approval this year in North Dakota and Montana, key target markets for growing spring wheat. Additional commercial scale trials are planned for 2021, in preparation for product launch planned for 2022. Lavie Bio intends to evaluate potential expansion of LAV211 to additional crops.

Bio-stimulant for Corn – This program is in the pre-development phase.[2] Following results obtained in recent seasons, a subset of candidates is expected to undergo further optimization and additional trials. In addition, during 2021, potential expansion opportunities of the candidates for additional crops are expected to be evaluated. Part of this program is under Lavie Bio's collaboration with Corteva, Inc. (previously DuPont).[3]

Bio-pesticides pipeline:

LAV311 & LAV312 Targeting Bunch Rot Diseases – Chemical crop protection expenditure for bunch rot diseases is estimated at over $200 million annually.[4] Bio-fungicides LAV311 and LAV312 are designed to integrate into the farmer's existing IPM (Integrated Pest Management) practices. Lavie Bio's initial focus is on grapes and it intends to broaden this solution to other fruit.

As announced last month, LAV311 and LAV312 advanced to "Development Stage 2".[5] This follows successful results in vineyard trials, conducted in target locations in Europe and the U.S. The trials' results showed significantly better efficacy and consistency than existing comparable tested commercial biological benchmarks and were competitive to tested commercial chemical benchmarks. In 2021, Lavie Bio intends to further improve the formulation technology and fermentation protocol of LAV311 and LAV312 and expand these solutions to additional crops. Lavie Bio is targeting a product launch for 2024.

Bio-fungicides Targeting Downy Mildew – Downy mildew is a devastating disease with an urgent need for new solutions. Current chemical crop protection expenditure against downy mildew is estimated at over $350 million annually.[4] Lavie Bio's initial focus is on grapes and it intends to broaden its solution to other fruit and vegetable crops.

During 2020, Lavie Bio tested leading candidates that demonstrated positive preliminary results in field trials. Additional candidates were introduced into the pipeline and underwent lab and greenhouse testing. In 2021, select candidates are expected to be tested in target locations in Europe.

Bio-fungicides Targeting Seedling Diseases – The average annual expenditure for crop protection against seedling diseases is over $500 million,4 with leading commercial chemicals under regulatory pressure and resistance emergence posing a risk. Lavie Bio believes that biological solutions have the potential to play an important role in addressing these challenges. Lavie Bio's initial focus is on corn and it intends to expand its solution to soybean and other crops.

In 2020, Lavie Bio's new candidates were validated in lab and greenhouse trials with positive results. Leading candidates are undergoing further development with field testing planned for target locations during 2021.

Bio-insecticides Targeting Western Corn Root Worm (WCRW) – The annual overall expenditure on protection against WCRW, including genetically modified corn seed traits (biotech traits) and chemical insecticides, exceeds $1.5 billion.[6] Biological insecticides could be integrated into the farmer's existing IPM either with biotech traits or combined with chemical solutions. During 2019-2020, Lavie Bio introduced additional candidates to its pipeline, which were validated in lab, greenhouse and field trials. In 2021, Lavie Bio expects to test leading candidates in multi-location fields in target territories and in parallel further optimize their formulations.

Mr. Ido Dor added: "The sustainable approach of ag-biologicals holds a significant promise for the future of agriculture, and we are excited to be at the forefront of this area. We are confident Lavie Bio has an excellent opportunity, powered by our Biology Driven Design (BDD) platform, to make a real impact for both growers and consumers and look forward to sharing our progress over the coming year, as our vision advances towards commercialization of our initial products."

Mr. Ofer Haviv, Chairman of Lavie Bio and CEO & President of Evogene, stated: "We are pleased with the progress that Lavie Bio achieved in its product pipelines in 2020. The use of Lavie Bio's computational BDD platform, powered by Evogene's 'MicroBoost AI' engine, has led Lavie Bio to reach impressive achievements in multiple product pipelines. I am confident that Lavie Bio is on the right track to becoming a global leading ag-biologicals company, introducing multiple novel products in the coming years."

About the Biology Driven Design (BDD) Platform

The BDD platform facilitates and accelerates the design and development of microbiome-based products through the decoding of complex microbiome/host interactions and the identification of the key genetic elements (functions) governing these interactions. This decoding, which enables amplification of positive or elimination of negative, and/or the retrieval of lost interactions, is powered by big data and artificial intelligence, provides the basis for products design. The enabling technology for the establishment of the BDD platform was the MicroBoost AI engine, a component of Evogene's Computational Predictive Biology (CPB) platform and the Taxonia platform acquired as part of the Taxon Biosciences acquisition.

About Lavie Bio Ltd.:

Lavie Bio, a subsidiary of Evogene Ltd., aims to improve food quality, sustainability and agriculture productivity through the introduction of microbiome based ag-biological products. Lavie Bio utilizes a proprietary computational predictive platform, the BDD platform, harnessing the power of big data and advanced informatics, for the discovery, optimization and development of bio-stimulants and bio-pesticides products. Corteva, Inc. holds approximately 28% in Lavie Bio. For more information, please visit www.lavie-bio.com.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN) (TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ag Ltd. For more information, please visit www.evogene.com.

[midastouch017]

5.37+1.44 (+36.62%)
As of 1:03PM EST. Market open.
Just broke (again) the 52 w/h

[midastouch017]

5.21+1.28 (+32.57%)
As of 12:48PM EST. Market open.

Volume 5,005,609
Avg. Volume 1,135,076

WoW!

[midastouch017]

Canonic Announces Signing of First Cultivation Agreement for its Medical Cannabis Varieties

Wed, December 23, 2020, 2:00 PM GMT+2

Recent agreement with Telcann for plant growth services completes major component in production infrastructure for planned product commercialization in Israel in 2022

REHOVOT, Israel, Dec. 23, 2020 /PRNewswire/ -- Canonic Ltd, a company focused on the development of medical cannabis products and a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) announced today that it has signed its first commercial agreement with a licensed medical cannabis cultivator, Telcann Ltd, for the provision of plant growth services in Israel to Canonic. With this agreement, Canonic has completed the establishment of the major component required for the production infrastructure of its medical cannabis products, MetaYield and Precise in Israel. Canonic is expected to proceed with the execution of its commercialization (go-to-market) plan of medical cannabis products in Israel under its own label. Canonic's first product, from its MetaYield program, is aimed to be commercialized commencing in 2022.

According to statistics, published by Israeli Medical Cannabis Agency (IMCA)[1], in 2020 there are approximately 75,000 active patients in Israel that consume a total of roughly 30 tons of cannabis per year, which translate to $220 million per year2. Based on current growth rates, according to industry estimates the Israeli market will reach approximately 250,000 patients by 20253.

Canonic aims to market its medical cannabis products under its own label to pharmacies and distributors in Israel. Canonic intends to establish a value chain from genomics to the end product, with certain parts of the value chain outsourced to sub-contractors such as cultivation, production and distribution. Canonic aims to focus on aspects in which it has a competitive advantage, such as the development of cannabis varieties seeds and seedlings.

Telcann is a leading medical cannabis cultivator in Israel, licensed by the Israel medical cannabis agency (IMCA) and has 130,000 sq. ft. of greenhouses including the required post- harvest capabilities. Canonic entered this agreement with Telcann, after evaluating its high agronomic standards and initiating a pilot growth trial of its seedlings at Telcann's facility. Telcann provides services to additional cannabis companies in Israel.

Under the agreement, Canonic expects to deliver a first batch of its medical cannabis seedlings to Telcann during 2021, originating from Canonic's propagation farm, which recently received IMC-GAP approval from the IMCA. These seedlings are expected to be grown to maturity, harvested and processed by Telcann and later transferred to a third-party GMP production facility for further processing and preparation for marketing.

In parallel to this, Canonic is advancing development activities to achieve a first commercial cannabis variety, under its MetaYield program. In addition, in order to complete the commercial framework for its activities, in 2021 Canonic aims to enter definitive production and distribution agreements to support the commercialization of its first product in 2022.

Dr. Arnon Heyman, CEO of Canonic stated: "We are pleased to partner with Telcann, a leading cannabis cultivator as we move forward in bringing highly precise and stable medical-cannabis products to the market. With this agreement Canonic has completed a fundamental element of its production infrastructure towards becoming a commercial medical cannabis company."

Mr. Ofer Haviv, Chairman of Canonic and CEO & President of Evogene stated: "I am pleased to see that within a very short time, Canonic has created an impressive operation, which we expect will come into full fruition in 2022 with first sales of medical cannabis in Israel. I am confident that access to Evogene's GeneRator AI engine will be a significant contributing factor in the success of Canonic to bring to market genetically unique cannabis products."

About Canonic Ltd.:

Canonic is a subsidiary of Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), developing medical Cannabis products through a Computational Predictive Biology (CPB) platform. The Company's products in development are aimed at improving active compounds yield, genetic stability and Cannabis varieties for specific medical indications. The Company's strategy includes the development of Cannabis varieties in order to commercialize medical Cannabis products independently or through collaborations. Canonic has exclusive access to Evogene's genomic assets and technology for the development of medical Cannabis products. For more information, please visit: https://www.canonicbio.com/.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN), (TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ltd. For more information, please visit www.evogene.com.

[midastouch017]

And glad to have you on this board

Thank you ontologizer.



You can find additional info re EVGN in this site,
including stock quotes even on Sunday.
[TASE operates SUNDAY thru THURSDAY iclu]


https://www.tase.co.il/en/market_data/company/001461/about

[ontologizer]

Thank you midas, that's the goal. Glad you're getting to enjoy your retirement. And glad to have you on this board, 'Midas' :)

[midastouch017]

I wish I had as much time as you!

When you get to be my age, i hope for you
will have more time at hand!
Stay safe!

[ontologizer]

Yup, dropped back down. I stay away from after/pre-market hours just for that reason.

[ontologizer]

I wish I had as much time as you! Busy grading papers for high school students, ugh. Tracking DSGT more closely though.

I feel good about EVGN, just being part of ARK's holdings, it gets more visibility (and they seem to finally be getting more results). I've seen it first hand for other stocks.

[midastouch017]

Since i am on pension with a lot of
time on my hands, i do track a few
companies, in both languages as they
are dually traded, as you already
know.

[ontologizer]

But I do appreciate the update! Figured this could be a good place to track news/updates.

[ontologizer]

hmmm, wonder why(?)... not exactly expecting it to pop out the gates.

I'm not really tracking this stock day to day. I figure it'll double, maybe in a month, maybe in 3, but not after too long.

[midastouch017]

Nice p/m activity:

Evogene Ltd (EVGN)
3.9899 ^ 0.2699 (7.26%)
Volume: 8,474 @12/18/20 8:24:35 AM EST

[ontologizer]

I was a bit surprised about the drop after the most recent press release, relating to achieving lead status, but great opportunity to buy more.

If Ark Invest includes a blurb on Monday that might help light the fire. If not, just an extended window to buy.

The late January presentation for Biomica I believe is the next catalyst. However, they have already mentioned that there was a 50% increase in ORR (overall response rate) with regards to reduction of tumor size. This will again be validation of the platform.

[midastouch017]

This message board is far too inactive given
the upside potential of this company:

I fully agree, the potential is indeed
huge, with all the affiliated companies,
daughter companies and various cooperations.
BTW, EVGN is dually traded, in TASE (Tel
Aviv Stock Exchange as well as the Nasdaq)

++++++++++++++++++++++++++++++++++++++

Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA)
is a leading computational biology company
targeting to revolutionize life-science
product development.

https://www.evogene.com/investor-relations/

BTW 2 - An insightful interview with CEO dated
Sep 2020. It is in Hebrew but Goog translate
will give you a good impression of the contents:

https://www.bizportal.co.il/capitalmarket/news/article/784272

[ontologizer]

This message board is far too inactive given the upside potential of this company:

Earlier today, AgPlenus Announces Reaching a 'Lead' Stage in its Novel Mode-of-Action Herbicide Program
https://www.prnewswire.com/news-releases/agplenus-announces-reaching-a-lead-stage-in-its-novel-mode-of-action-herbicide-program-301192730.html
An important milestone providing further validation of evogene's computational platform for molecule/microbe discovery.

Steven Goldman provides multiple articles providing good coverage of each of the companies subsidiaries. Here is one:
https://seekingalpha.com/article/4372111-evogene-hidden-gems-of-computational-predictive-biology-part-3-of-4-ag-plenus-novel

Ark invest has invested into this company. Of the microcap companies that Ark has in the holdings - aquabounty, nano dimensions - they have an excellent track record for selecting winners.

Upcoming catalyst: The subsidiary Biomica is presenting their full data in late January on one of their candidate molecules which has shown success in animal models.

Currently just below $4, the one analyst covering them has given them a $9 price target, representing a ~225% upside.

This is a long term hold for me as comparable companies hold market caps of and around $1 billion and the current market cap is at $150 million. Furthermore, the company, through it's subsidiaries offers a broad portfolio of products for herbicides, pesticides, cancer, and medical grade of development. All still in early stages.

[whytestocks]

News; $EVGN Evogene Reports Third Quarter 2020 Financial Results

Evogene Reports Third Quarter 2020 Financial Results Conference call and webcast: today, November 18th, 9:00 a.m. ET PR Newswire REHOVOT, Israel, Nov. 18, 2020 REHOVOT, Israel , Nov. 18, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), ...

Find out more EVGN - Evogene Reports Third Quarter 2020 Financial Results

[whytestocks]

NEWS: $EVGN Making A List Of Penny Stocks? 5 Small Cap Stocks Under $4 To Watch

Are These On Your List Of Small Cap Stocks Today? While the technical definition of small cap penny stocks is shares of companies with market caps between $300 million to $2 billion, the term has been loosely used to describe all penny stocks . It’s a common misconception...

In case you are interested EVGN - Making A List Of Penny Stocks? 5 Small Cap Stocks Under $4 To Watch

[whytestocks]

NEWS: $EVGN Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program

Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program The company is advancing to scale-up and GMP batch production, to support anticipated first-in-man proof-of-concept clinical trials next yea...

Find out more EVGN - Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program

[saigai]

the more i read here the more i think of a google type algorithm .their predictive tech/AI is gonna be MONSTROUS

[saigai]

bought in a few days back. wish i had caught it yesterday but looks very strong long term

[whytestocks]

NEWS: $EVGN What Are The Top Penny Stocks To Buy Today? 3 Up Big In 2020

Looking For Penny Stocks To Buy? Buying penny stocks can be a high-risk endeavor for any trader. However, the rewards can be sweet. Considering that you’ve got a lot of headwinds going into a trade, it’s important to research, first. It’s also important to outli...

Read the whole news EVGN - What Are The Top Penny Stocks To Buy Today? 3 Up Big In 2020

[whytestocks]

News; $EVGN Putting Together A List Of Penny Stocks? 3 To Watch Right Now

Are These On Your Penny Stocks List This Week? What a wild week it has been for penny stocks . September is really one of the craziest months of the second half so far. First, it was a month with fewer trading days. Second, we also saw an uptick in general market concern amid a pote...

Find out more EVGN - Putting Together A List Of Penny Stocks? 3 To Watch Right Now

[whytestocks]

News; $EVGN These Penny Stocks On Robinhood Are Outperforming Blue Chips In 2020

3 Robinhood Penny Stocks To Watch This Year Blue chips are great but nothing compares to penny stocks . To put the two in the same setting is a bit confusing. For one, penny stocks are more actively day traded than anything else. Don’t get me wrong, there are cases where investing in p...

Find out more EVGN - These Penny Stocks On Robinhood Are Outperforming Blue Chips In 2020

[TFMG]

$EVGN | #Evogene Ltd. Potential Breakout


Evogene Ltd. operates as a plant genomics company. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. It also offers a solution for crop productivity improvement through biotechnology and breeding using a technology infrastructure that is based on deep scientific understanding of plant genomics and proprietary computational capabilities. The company was founded by Amir Barzilay and Hagai Karchi in 2002 and is headquartered in Rehovot, Israel.

[Golden Cross]

EVGN Cross of the 50/200sma today!

$EVGN Cross of the 50/200sma today! pic.twitter.com/TmhaM8lpKd

— 💸 Golden Cross Stocks 💸 (@CrossStocks) September 3, 2020

[whytestocks]

NEWS: $EVGN Evogene Announces $10 Million Equity Led Investment by ARK Investment Management, LLC

REHOVOT, Israel , Sept. 1, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, today announ...

Read the whole news EVGN - Evogene Announces $10 Million Equity Led Investment by ARK Investment Management, LLC

[midastouch017]

Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing
June 03 2020 - 07:00AM

PR Newswire (US) Print

REHOVOT, Israel, June 3, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its participation in the CRISPR-IL consortium. The goal is to develop "Go-Genome", an artificial intelligence (AI) based, end-to-end system for genome-editing to be used in multi-species for pharma, agriculture, and aquaculture. Evogene's CSO, Dr. Eyal Emmanuel will serve as the Chairman of the consortium.

The CRISPR-IL consortium has been approved for 1.5 years by the Israeli Innovation Authority and may be extended to an additional 1.5 years. The consortium's total budget (for the first period) is approximately ILS 36 million (roughly $10 million), partially funded by a grant from the Israeli Innovation Authority. CRISPR-IL participants include leading companies, medical institutions, and academic institutions. Apart from Evogene, key participants include BTG – Bio-technology General Israel, Colors Farm, Hazera Seeds, NRGene, Pluristem, Rahan Meristem Ltd., TargetGene; medical institutions: Sheba Medical Center, Schneider Children's Medical Center; and academia: Bar-Ilan University, Ben Gurion University of the Negev, Hebrew University of Jerusalem, IDC Herzliya, Tel-Aviv University and the Weizmann Institute.

CRISPR is a genome-editing technology for detecting and modifying DNA sequences. It is used as a tool to enable precise genetic alterations without the introduction of foreign DNA. The technology enables the development of unique bio-based products and novel therapeutics while reducing the time and cost of development. Current CRISPR-based workflows target precise areas within the DNA, however, these workflows still face several challenges, which prevent more extensive use of this tool, including: (i) accidental off-target modification, (ii) inefficient modifications and (iii) inaccurate measuring tools to ascertain that the modification was effective as intended.

The CRISPR-IL consortium intends to develop an artificial intelligence-based system, "Go-Genome", providing users improved genome-editing workflows. The system aims to provide end-to-end solutions, from user interface to an accurate measurement tool. The system is expected to include the computational design of on-target DNA modification, with minimal accidental, off-target modifications, improve modification efficiency and provide an accurate measuring tool to ensure the desired modification was made. This system intends be designed to be effective in multi-species, including human, plant, and certain animal DNA applicable to market segments in pharma, agriculture and aquaculture.

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.

Dr. Eyal Emmanuel, Chairman of the CRISPR-IL consortium and CSO of Evogene commented: "Our mission is to position Israel as a top technological hub for the use of AI in genome editing. The all-encompassing system the consortium aims to develop, is expected to expand the scope of Evogene's discovery and development offerings for genetic elements, including for its subsidiaries. We believe this is a unique opportunity for applying computational biology and artificial intelligence to genome editing. We are excited to be leading this effort through decoding biology."

Prof. Avraham A. Levy, Chairman of Evogene's Scientific Advisory Board and Dean of the Biochemistry faculty at the Weizmann Institute of Science commented: "The workplan proposed by Evogene within the CRISPIL consortium addresses important gaps in our scientific understanding of the CRISPR technology. Evogene's unique computational analytical tools, together with the data produced by the consortium, have the potential to enable a more effective utilization of genome editing in medicine and agriculture, paving the road for novel products and treatments."

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN.TA) is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

For more information, please visit www.evogene.com

[whytestocks]

News: $EVGN Corteva Agriscience to Invest in Evogene's Agriculture Biologicals Subsidiary, Lavie Bio

WILMINGTON, Del. and   REHOVOT, Israel , Aug. 7, 2019 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA), a leading pure-play agriculture company, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today t...

Find out more Corteva Agriscience to Invest in Evogene's Agriculture Biologicals Subsidiary, Lavie Bio

[whytestocks]

News: $EVGN Evogene to Develop Next Generation Medical Cannabis Products Through New Subsidiary - Canonic Ltd

REHOVOT, Israel , April 3, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it has established a new subsidiary – Canonic Ltd – to develop next generation m...

Read the whole news https://marketwirenews.com/news-releases/evogene-to-develop-next-generation-medical-cannabis-products-through-new-subsidiary-canonic-ltd-7938964.html

[Full Contact Yoga]

Not sure why this ticker would need broker assistance to purchase....haven't had that happen in a long time and never with a legit stock. Haven't tried all brokers, but, no is no, I will take the sign as such and leave it alone....

[crudeoil24]

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it has established a new subsidiary - Canonic Ltd - to develop next generation medical cannabis products. Evogene has been evaluating the medical cannabis field for more than a year, including market evaluation, obtaining governmental approvals for its research program and the establishment of a research facility, technology assessment and initial product line planning. Canonic's initial activities will focus on creating improved cannabis varieties by addressing the current developmental roadblocks of yield, stability and specific metabolite composition. These development efforts will be based on the utilization of Evogene's broadly applicable leading Computational Predictive Biology (CPB) platform, which has in the past demonstrated success in addressing similar objectives for other crops.

https://mma.prnewswire.com/media/803468/Evogene_Ltd_Logo.jpg

The current cannabis market is estimated at ~$13 billion and is expected to grow to ~$24 billion by 2025[1]. Although the cannabis market is growing rapidly, it is well recognized that next generation products will need to address the current limitations of: (i) low metabolite yield - causing high costs for patients, (ii) low variety stability - causing inconsistent products that have become unreliable as a medical treatment and (iii) uncertainty in connecting cannabis metabolite profile to specific medical indications.

Evogene is uniquely positioned to provide a significant competitive advantage in the resolution of these development roadblocks through its CPB platform and its recognized capabilities as a leader in the area of plant genomics. These capabilities have been developed and utilized for more than a decade through multiple collaborations with world leading ag-companies such as BASF, Bayer, Corteva, ICL and Monsanto focusing on crop improvement via plant genomics and are now expected to allow Evogene's newly established subsidiary, Canonic, to not only meet the challenges but also to accelerate the product development process through its predictive science driven approach.

Canonic's current workplan focuses on three main product types, through a non-GMO approach: (i) high metabolite yield cannabis varieties (ii) stable varieties with consistent metabolite performance and (iii) cannabis varieties with a unique metabolite profile tailored to specific medical indications. The indications that the company will currently address are: post-traumatic stress disorder (PTSD), severe chronic pain and cancer.

Dr. Arnon Heyman, Canonic CEO stated: "Having led Evogene's Ag-Seeds division for the past few years, I am proud to now lead Evogene's cannabis activity as Canonic's CEO. Evogene's cutting edge genomic technology, alongside our multidisciplinary team of professionals, uniquely positions Canonic to bring to market the most advanced, stable and consistent next-generation medical cannabis products, and I am confident we can make a significant impact in the world of medical grade cannabis."

[DewDiligence]

EVGN 3Q17 results:

https://globenewswire.com/news-release/2017/11/22/1205013/0/en/Evogene-Reports-Third-Quarter-2017-Financial-Results.html

[DewDiligence]

EVGN shakes up organization chart:

https://globenewswire.com/news-release/2017/10/30/1159882/0/en/Evogene-Announces-Revised-and-Expanded-Market-Focus-and-New-Corporate-Structure.html

[DewDiligence]

EVGN inks corn-seed collaboration with DD:

#msg-133319769
#msg-133319801

[wiltonio]

Migdal Insurance & Financial Holdings Ltd. has filed a new 13G, reporting 7.68% ownership in $EVGN - https://fintel.io/i13d/migdal-insurance-financial-holdings

[DewDiligence]

EVGN, SYT modify collaboration wrt soybean nematode: #msg-116267818.

[DewDiligence]

EVGN had $110M in cash at 6/30/15, a reduction of $3.2M during 2Q15:

http://finance.yahoo.com/news/evogene-reports-second-quarter-2015-110500034.html

[DewDiligence]

EVGN had $113.2M of cash at 3/31/15:

http://finance.yahoo.com/news/evogene-reports-first-quarter-2015-110500821.html

[10baggerlong]

EVGN rated a "top pick" by Credit Suisse:


Credit Suisse’s Top Agriculture Stock Picks for 2015


Read more: http://247wallst.com/commodities-metals/2015/01/14/credit-suisses-top-agriculture-stock-picks-for-2015/#ixzz3XzK39HBx

[DewDiligence]

EVGN inks 3-year collaboration with undisclosed food company:

http://finance.yahoo.com/news/evogene-discloses-first-collaboration-leading-120000804.html

No financial details.

[DewDiligence]

EVGN had $116.3M of cash at 12/31/14:

http://finance.yahoo.com/news/evogene-reports-fourth-quarter-full-120500547.html

[DewDiligence]

Individual traits per se do not go through field trials; rather, product candidates (which may consist of several stacked traits ) do.

[mr_o]

EVGN future questions

Dew, I know very little about EVGN and plant gene-trait discovery, so apologies for dumb questions in advance. That being said, how long does it take a phase 2 gene trait to get approved for marketing? Also, what kind of probability does a plant gene-trait have to make it through all trials and get approval?

EVGN currently looks interesting on the surface. A market cap of 230 million, 100 million in cash and 10 partnerships for future products. At this point, I simply have no idea how to ascribe value a plant gene-trait partnership.

[DewDiligence]

EVGN establishes R&D facility in St. Louis, which just happens to be where MON is headquartered:

http://www.sec.gov/Archives/edgar/data/1574565/000117891315000301/exhibit_99-1.htm

The two companies recently expanded their R&D partnership.

[DewDiligence]

EVGN engages CNH to develop harvester for castor beans:

http://finance.yahoo.com/news/cnh-industrial-evogene-subsidiary-announce-110000233.html

Financial terms are not disclosed.

[DewDiligence]

EVGN reports 3Q14 results:

http://www.sec.gov/Archives/edgar/data/1574565/000117891314003417/exhibit_99-1.htm

[DewDiligence]

EVGN’s investor slide set (updated):

http://www.sec.gov/Archives/edgar/data/1574565/000117891314002927/exhibit_99-1.htm

[DewDiligence]

EVGN, MBII collaborate on insect resistance: #msg-104556758.